{"nctId":"NCT00811720","briefTitle":"Efficacy of Nalmefene in Patients With Alcohol Dependence","startDateStruct":{"date":"2008-12"},"conditions":["Alcohol Dependence"],"count":598,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Nalmefene","type":"EXPERIMENTAL","interventionNames":["Drug: Nalmefene"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Nalmefene","otherNames":["Selincro™"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nIn- and outpatients who:\n\n* had a primary diagnosis of alcohol dependence according to Diagnostic and Statistical Manual of Mental Disorders - Text revision (DSM-IV-TR) criteria\n* had had ≥6 HDDs in the 4 weeks preceding the Screening Visit\n* had had an average alcohol consumption at WHO medium risk level or above in the 4 weeks preceding the Screening Visit\n\nExclusion Criteria:\n\nThe patient:\n\n* had a DSM-IV Axis I disorder other than alcohol dependence or nicotine dependence\n* had an antisocial personality disorder\n* had risk of suicide evaluated by the suicidality module of the Mini-International Neuropsychiatric Interview (MINI)\n* had a history of delirium tremens or alcohol withdrawal seizures\n* reported current or recent (within 3 months preceding screening) treatment with disulfiram, acamprosate, topiramate, naltrexone or carbimide, or with any opioid antagonists\n* reported current or recent treatment with antipsychotics or antidepressants\n* was pregnant or breast-feeding\n\nOther protocol-defined inclusion and exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)","description":"Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 grams (g) for men and ≥40 g for women.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.91","spread":"0.56"},{"groupId":"OG001","value":"-11.24","spread":"0.60"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in the Monthly Total Alcohol Consumption (TAC)","description":"TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.70","spread":"2.25"},{"groupId":"OG001","value":"-50.66","spread":"2.41"}]}]}]},{"type":"SECONDARY","title":"Drinking Risk Level (RSDRL) Response","description":"RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.3","spread":null},{"groupId":"OG001","value":"36.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Status Using CGI-S","description":"The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.90","spread":"0.08"},{"groupId":"OG001","value":"-1.27","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change in Clinical Status Using the CGI-I","description":"The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.65","spread":"0.07"},{"groupId":"OG001","value":"2.30","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Liver Function Test Gamma-glutamyl Transferase (GGT)","description":"GGT values","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.7","spread":"56.2"},{"groupId":"OG001","value":"40.3","spread":"52.5"}]}]}]},{"type":"SECONDARY","title":"Liver Function Test Alanine Aminotransferase (ALAT)","description":"ALAT values","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.1","spread":"44.7"},{"groupId":"OG001","value":"25.4","spread":"42.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":296},"commonTop":["Dizziness","Nausea","Fatigue","Nasopharyngitis","Headache"]}}}